Streetbeat News

Stock Prices

CPAY

Analysts have provided mixed ratings for Corpay (NYSE:CPAY) in the latest quarter, with a range of bullish to bearish perspectives. The average 12-month price target is $336.0, reflecting a slight increase from the previous target. Corpay has shown solid revenue growth and strong financial health, but its high debt-to-equity ratio raises concerns.

Portfolio Pulse from Benzinga Insights

June 21, 2024 | 4:00 pm

F

GM

TSLA

Hyundai Motor Company is launching two new electric vehicles in Europe, the Inster EV and a new IONIQ model, to boost its market share. Despite rivals like General Motors, Ford, and Tesla scaling back, Hyundai is pushing forward. The Inster EV will debut at the Busan International Mobility event on June 27th. Hyundai's IONIQ 5 set a new sales record in May, and the company is opening its first EV and battery plant in the US later this year. Hyundai and Kia are closing the market share gap with Tesla in the US.

Portfolio Pulse from Upwallstreet

June 21, 2024 | 3:56 pm

BIDU

HAO

Haoxi Health Technology Ltd. (NASDAQ:HAO) saw its shares drop by 28% after announcing plans to raise additional funds just six months after its IPO. Despite strong financial growth, investor confidence waned due to concerns over the company's heavy reliance on ByteDance and rising accounts payable.

Portfolio Pulse from The Bamboo Works

June 21, 2024 | 3:53 pm

3iQ Corp

BTCUSD

SOLUSD

Solana (SOL) is experiencing a continuous decline, prompting concerns from prominent traders. Despite Bitcoin's stability, SOL is down 37% from its peak. However, some influencers remain bullish, citing its resilience at the $125 support level. Additionally, 3iQ Corp plans to launch North America's first Solana-based ETP in Canada.

Portfolio Pulse from Khyathi Dalal

June 21, 2024 | 3:46 pm

CLSK

COIN

MARA

RIOT

Shares of crypto-related stocks are trading lower amid a drop in Bitcoin.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:42 pm

GILD

LLY

MRK

NVO

PFE

Gilead Sciences (GILD) faces speculation about entering the obesity drug market, but remains focused on liver treatments, particularly NASH. Despite a brief stock surge, analysts doubt Gilead's competitiveness in obesity drugs. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) lead the obesity drug market, while others like Pfizer (PFE) and Merck (MRK) explore opportunities.

Portfolio Pulse from Vandana Singh

June 21, 2024 | 3:42 pm

ASAN

Asana shares are trading higher following the announcement of a $150 million stock repurchase program.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:40 pm

AXP

IPAY

JRNY

SQSP

American Express (AXP) has agreed to acquire Tock from Squarespace (SQSP) for $400 million and Rooam for an undisclosed amount. These acquisitions aim to enhance American Express's restaurant and payment technology offerings. The deals are subject to regulatory approval. AXP shares are down 0.53% at $229.00.

Portfolio Pulse from Lekha Gupta

June 21, 2024 | 3:40 pm

IBRX

ImmunityBio shares are trading higher following the announcement of insurance coverage for ANKTIVA across multiple states and the administration of the first commercial doses.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:40 pm

BA

SPY

The New York Times reported that Boeing is expected to evade criminal charges for violating a settlement agreement with the Department of Justice. This development could have implications for Boeing's stock and the broader market.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:37 pm